Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy
Abstract Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The phase III EXPLORER‐HCM (NCT03470545) study used a dose‐titration scheme based on mavacamten exposu...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2024-09-01
|
| Edice: | CPT: Pharmacometrics & Systems Pharmacology |
| On-line přístup: | https://doi.org/10.1002/psp4.13138 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|